Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: SurModics

Market Cap 427M 369M 340M 319M 597M 40.92B 607M 4.03B 1.57B 19.72B 1.6B 1.57B 68.41B P/E Ratio 2023
-292x
P/E Ratio 2024 -47.3x
Enterprise Value 420M 363M 334M 313M 587M 40.26B 597M 3.96B 1.54B 19.41B 1.58B 1.54B 67.31B EV / Sales 2023
3.33x
EV / Sales 2024 4.33x
Free-Float
99.63%
Yield 2023 *
-
Yield 2024 -
1 year 25.87
Extreme 25.87
43
3 years 22.15
Extreme 22.15
43
5 years 16
Extreme 16
62.27
10 years 16
Extreme 16
82.35
Manager TitleAgeSince
Chief Executive Officer 67 2025-11-18
Director of Finance/CFO 53 2025-11-18
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 67 2025-11-18
Director/Board Member 53 2025-11-18
Date Insider Type Main position Quantity % Market Cap.
11-18Issuer sale

Director

35,847 0.2507%
11-18Issuer sale

Director

62,052 0.4340%
11-18Issuer sale

Director

51,877 0.3628%
Change 5-day change 1-year change 3-year change Capi.($)
+0.35%-.--%+47.19%+92.05% 615M
+0.54%+3.06%-33.16%-11.84% 155B
+0.10%+3.05%-8.67%-4.06% 103B
+0.09%+6.77%-0.97%+57.94% 54.72B
-0.23%-6.71%+50.66%+49.87% 53.65B
-0.30%+1.19%-15.51%-41.41% 40.72B
+1.61%+7.72% - - 30.9B
+0.64%+3.41%-11.28%-39.48% 28.85B
-0.18%+4.44%+45.08%-5.15% 23.38B
-1.93%-0.66%-14.31%+2.17% 21.22B
Average -0.16%+2.33%+6.56%+11.12% 51.24B
Weighted average by Cap. +0.09%+2.29%-7.39%+1.55%

Financials

2023 2024
Net sales 133M 115M 105M 98.84M 185M 12.69B 188M 1.25B 486M 6.12B 498M 487M 21.22B 126M 109M 100M 93.99M 176M 12.07B 179M 1.19B 462M 5.82B 473M 463M 20.18B
Net income -1.54M -1.33M -1.22M -1.15M -2.15M -147M -2.18M -14.48M -5.63M -70.89M -5.77M -5.64M -246M -11.54M -9.97M -9.18M -8.6M -16.12M -1.11B -16.38M -109M -42.32M -533M -43.33M -42.39M -1.85B
Net Debt -12.1M -10.45M -9.62M -9.02M -16.9M -1.16B -17.18M -114M -44.37M -558M -45.43M -44.45M -1.94B -6.87M -5.94M -5.46M -5.12M -9.6M -658M -9.75M -64.76M -25.19M -317M -25.79M -25.23M -1.1B
Logo SurModics
Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
Employees
389
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. SRDX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!